Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 6 (2009), Issue 6 (June)

  1. Comparison of CT on rails with electronic portal imaging for positioning of prostate cancer patients with implanted fiducial markers.
    Int J Radiat Oncol Biol Phys, 74(3): 906-12. [Abstract] [Full-text]
  2. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
    Urology, 73(6): 1328-34. [Abstract] [Full-text]
  3. Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort.
    Urology, 73(6): 1323-7. [Abstract] [Full-text]
  4. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
    Urology, 73(6): 1342-6. [Abstract] [Full-text]
  5. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
    Urology, 73(6): 1347-51. [Abstract] [Full-text]
  6. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
    Urology, 73(6): 1407-11. [Abstract] [Full-text]
  7. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Int J Radiat Oncol Biol Phys, 74(3): 759-65. [Abstract] [Full-text]
  8. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
    Eur J Cancer, 45(9): 1664-72. [Abstract] [Full-text]
  9. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 74(3): 753-8. [Abstract] [Full-text]
  10. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.
    Adv Drug Deliv Rev, 61(7): 572-88. [Abstract] [Full-text]
  11. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.
    Clin Cancer Res, 15(11): 3842-9. [Abstract] [Full-text]
  12. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Prostate, 69(10): 1128-41. [Abstract] [Full-text]
  13. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
    Prostate, 69(10): 1109-18. [Abstract] [Full-text]
  14. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer.
    Prostate, 69(10): 1091-100. [Abstract] [Full-text]
  15. Predictors of patient reported outcomes and cost of care in younger men with newly diagnosed prostate cancer.
    Prostate, 69(10): 1067-76. [Abstract] [Full-text]
  16. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
    Prostate, 69(10): 1034-44. [Abstract] [Full-text]
  17. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Prostate, 69(10): 1101-8. [Abstract] [Full-text]
  18. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells.
    Prostate, 69(10): 1077-90. [Abstract] [Full-text]
  19. Optimizing molecular signatures for predicting prostate cancer recurrence.
    Prostate, 69(10): 1119-27. [Abstract] [Full-text]
  20. Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells.
    Prostate, 69(10): 1045-54. [Abstract] [Full-text]
  21. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.
    Prostate, 69(10): 1055-66. [Abstract] [Full-text]
  22. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas.
    Prostate, 69(10): 1025-33. [Abstract] [Full-text]
  23. Gene expression of forkhead transcription factors in the normal and diseased human prostate.
    BJU Int, 103(11): 1574-80. [Abstract] [Full-text]
  24. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    BJU Int, 103(11): 1472-7. [Abstract] [Full-text]
  25. Effect of ageing and body mass index on prostate-specific antigen levels among Chinese men in Singapore from a community-based study.
    BJU Int, 103(11): 1487-91. [Abstract] [Full-text]
  26. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
    BJU Int, 103(11): 1482-6. [Abstract] [Full-text]
  27. Outcome of radical prostatectomy for incidental carcinoma of the prostate.
    BJU Int, 103(11): 1478-81. [Abstract] [Full-text]
  28. Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
    Br J Cancer, 100(11): 1817-23. [Abstract] [Full-text]
  29. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk.
    Br J Cancer, 100(11): 1799-805. [Abstract] [Full-text]
  30. Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.
    Br J Cancer, 100(11): 1784-93. [Abstract] [Full-text]
  31. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.
    Life Sci, 84(25): 882-7. [Abstract] [Full-text]
  32. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
    J Steroid Biochem Mol Biol, 115(3): 126-36. [Abstract] [Full-text]
  33. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy.
    Cancer Sci, 100(6): 1047-50. [Abstract] [Full-text]
  34. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Cancer Chemother Pharmacol, 64(3): 445-54. [Abstract] [Full-text]
  35. Enhancement of sensitivity and specificity by surface modification of carbon nanotubes in diagnosis of prostate cancer based on carbon nanotube field effect transistors.
    Biosens Bioelectron, 24(11): 3372-8. [Abstract] [Full-text]
  36. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
    J Clin Oncol, 27(17): 2766-71. [Abstract] [Full-text]
  37. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
    J Clin Oncol, 27(17): 2772-8. [Abstract] [Full-text]
  38. Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy.
    Br J Cancer, 100(12): 1889-95. [Abstract] [Full-text]
  39. Suspected malignant cord compression - improving time to diagnosis via a 'hotline': a prospective audit.
    Br J Cancer, 100(12): 1867-72. [Abstract] [Full-text]
  40. Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer.
    Proc Natl Acad Sci U S A, 106(23): 9379-84. [Abstract] [Full-text]
  41. Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines.
    Br J Cancer, 100(12): 1852-60. [Abstract] [Full-text]
  42. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.
    Br J Cancer, 100(12): 1846-51. [Abstract] [Full-text]
  43. Current management of erectile dysfunction after cancer treatment.
    Curr Opin Oncol, 21(4): 303-9. [Abstract] [Full-text]
  44. Duration of androgen suppression in the treatment of prostate cancer.
    N Engl J Med, 360(24): 2516-27. [Abstract] [Full-text]
  45. Prostate cancer cognitive-behavioral factors in a West African population.
    J Immigr Minor Health, 11(4): 258-67. [Abstract] [Full-text]
  46. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.
    Hum Pathol, 40(7): 924-33. [Abstract] [Full-text]
  47. Lymphoepithelioma-like carcinoma of the prostate.
    Hum Pathol, 40(7): 982-7. [Abstract] [Full-text]
  48. Race/ethnicity and the perception of the risk of developing prostate cancer.
    Am J Prev Med, 37(1): 64-7. [Abstract] [Full-text]
  49. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
    Cancer Res, 69(12): 4937-40. [Abstract] [Full-text]
  50. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.
    Cancer Res, 69(12): 5202-9. [Abstract] [Full-text]
  51. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
    Cancer Res, 69(12): 5007-14. [Abstract] [Full-text]
  52. Activation of Rap1 promotes prostate cancer metastasis.
    Cancer Res, 69(12): 4962-8. [Abstract] [Full-text]
  53. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    J Natl Cancer Inst, 101(12): 888-92. [Abstract] [Full-text]
  54. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
    J Natl Cancer Inst, 101(12): 878-87. [Abstract] [Full-text]
  55. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    J Clin Oncol, 27(18): 2924-30. [Abstract] [Full-text]
  56. Family history of hormonal cancers and colorectal cancer risk: a case-control study conducted in Ontario.
    Int J Cancer, 125(4): 918-25. [Abstract] [Full-text]
  57. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
    Int J Cancer, 125(4): 932-41. [Abstract] [Full-text]
  58. Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer, 125(4): 902-8. [Abstract] [Full-text]
  59. CD4+ lymphocytes modulate prostate cancer progression in mice.
    Int J Cancer, 125(4): 868-78. [Abstract] [Full-text]
  60. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.
    Int J Cancer, 125(4): 774-82. [Abstract] [Full-text]
  61. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(4): 1217-25. [Abstract] [Full-text]
  62. Effectiveness of using fewer implanted fiducial markers for prostate target alignment.
    Int J Radiat Oncol Biol Phys, 74(4): 1283-9. [Abstract] [Full-text]
  63. Dosimetric effect of prostate motion during helical tomotherapy.
    Int J Radiat Oncol Biol Phys, 74(4): 1134-42. [Abstract] [Full-text]
  64. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Int J Radiat Oncol Biol Phys, 74(4): 1128-33. [Abstract] [Full-text]
  65. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
    Int J Radiat Oncol Biol Phys, 74(4): 1121-7. [Abstract] [Full-text]
  66. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
    Int J Radiat Oncol Biol Phys, 74(4): 1143-9. [Abstract] [Full-text]
  67. Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer.
    J Virol, 83(14): 6995-7003. [Abstract] [Full-text]
  68. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells.
    J Virol, 83(14): 7353-6. [Abstract] [Full-text]
  69. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
    Invest New Drugs, 27(4): 379-86. [Abstract] [Full-text]
  70. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis.
    Eur J Pharmacol, 615(1): 228-33. [Abstract] [Full-text]
  71. Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines.
    J Steroid Biochem Mol Biol, 116(1): 29-36. [Abstract] [Full-text]
  72. Finding a pathway: information and uncertainty along the prostate cancer patient journey.
    Br J Health Psychol, 14: 437-58. [Abstract] [Full-text]
  73. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters.
    Radiology, 252(1): 101-8. [Abstract] [Full-text]
  74. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study.
    Cancer, 115(13): 2863-71. [Abstract] [Full-text]
  75. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy.
    Cancer, 115(13): 2872-80. [Abstract] [Full-text]
  76. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma.
    Prostate, 69(11): 1245-55. [Abstract] [Full-text]
  77. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Prostate, 69(11): 1222-34. [Abstract] [Full-text]
  78. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Prostate, 69(11): 1195-205. [Abstract] [Full-text]
  79. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
    Prostate, 69(11): 1235-44. [Abstract] [Full-text]
  80. Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence.
    Prostate, 69(11): 1206-21. [Abstract] [Full-text]
  81. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
    Prostate, 69(11): 1188-94. [Abstract] [Full-text]
  82. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Prostate, 69(11): 1176-87. [Abstract] [Full-text]
  83. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.
    Prostate, 69(11): 1151-63. [Abstract] [Full-text]
  84. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.
    Prostate, 69(11): 1143-50. [Abstract] [Full-text]
  85. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
    Prostate, 69(11): 1164-75. [Abstract] [Full-text]
  86. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
    J Clin Oncol, 27(19): 3161-8. [Abstract] [Full-text]
  87. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
    J Clin Oncol, 27(19): 3177-84. [Abstract] [Full-text]
  88. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy.
    J Clin Oncol, 27(19): 3169-76. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

Surviving Prostate Cancer without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle

Surviving Prostate Cancer without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle